Thanh bên bài viết

Đã xuất bản: 2026-06-02
Số lượt xem tóm tắt: 27
DOI: https://doi.org/10.52163/yhc.v67iE1.5220
Số xuất bản
Tập 67 Số English Version No 1, 2026
Chuyên mục
Bài báo khoa học
Cách trích dẫn
Hung, P. V., Nam, N. T., Thoi, V. H., Khac, P. C., Hieu, N. H., & Dem, P. V. (2026). MYOCARDITIS FOLLOWING COVID-19 MRNA VACCINATION IN CHILDREN: REPORT OF TWO SEVERE PEDIATRIC CASES IN VIETNAM. Tạp Chí Y học Cộng đồng, 67(English Version No 1, 2026). https://doi.org/10.52163/yhc.v67iE1.5220

MYOCARDITIS FOLLOWING COVID-19 MRNA VACCINATION IN CHILDREN: REPORT OF TWO SEVERE PEDIATRIC CASES IN VIETNAM

Pham Van Hung1, Nguyen Thanh Nam1, Vu Huu Thoi1, Pham Cong Khac1, Nguyen Huu Hieu1, Pham Van Dem2,3
1 Pediatric Center, Bach Mai Hospital
2 University of Medicine and Pharmacy, Vietnam National University, Hanoi
3 Linh Dam Campus Hospital, University of Medicine and Pharmacy, Vietnam National University, Hanoi

Nội dung chính của bài viết

Tóm tắt

Introduction and objective: COVID-19 mRNA vaccines have demonstrated high efficacy; however, rare adverse events such as myocarditis have increasingly been reported. This report describes two cases of myocarditis occurring after the first vaccine dose, a presentation that remains uncommon in the literature.


Case presentation: Two previously healthy pediatric patients without underlying conditions presented with chest pain following mRNA vaccination. The first case had a moderate course with reduced ejection fraction (EF) and elevated cardiac enzymes, responding well to corticosteroid therapy. The second case presented with severe progression, including cardiogenic shock and complete atrioventricular block (third-degree AV block), requiring temporary pacing and vasopressor support.


Intervention and outcomes: Both patients received intensive medical treatment, including corticosteroids and cardiovascular support. Cardiac function and laboratory parameters fully recovered following treatment.


Conclusion: Myocarditis following mRNA COVID-19 vaccination is a rare but potentially severe adverse event, requiring close monitoring and timely management.

Chi tiết bài viết

Từ khóa

Acute myocarditis; COVID-19 mRNA vaccine

Tài liệu tham khảo

[1] Pfizer-BioNTech. Full emergency use authorization (EUA) prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=14471&format=pdf&#page=13. Accessed September 15, 2021.
[2] Ministry of Health. Information Gate of COVID-19 Vaccination. Available at: https://moh.gov.vn/. Accessed December 24, 2021.
[3] World Health Organization. Coronavirus disease (COVID-19): vaccines. Updated November 29, 2021. Available at: https://www.who.int/covid-19/vaccines. Accessed December 24, 2021.
[4] Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021;6(12):1446-1450. doi:10.1001/jamacardio.2021.3471
[5] Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132-2139. doi:10.1056/NEJMoa2110737
[6] Jain SS, Steele JM, Fonseca B, et al. COVID-19 vaccination–associated myocarditis in adolescents. Pediatrics. 2021;148(5):e2021053427. doi:10.1542/peds.2021-053427
[7] Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021;148(3):e2021052478.
[8] CARE Case Report Guideline. Oxford: Enhancing the Quality and Transparency of Health Research; 2021. Available at: https://www.care-statement.org/. Accessed November 27, 2021.
[9] Arola A, Pikkarainen E, Sipilä JO, et al. Occurrence and features of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc. 2017;6(11):e005306.
[10] Ghelani SJ, Spaeder MC, Pastor W, et al. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):622-627.